Genetic predisposition to heart failure

Michele Pasotti, Alessandra Repetto, Luigi Tavazzi, Eloisa Arbustini

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Because of its complexity, the list of susceptibility and modifier genes is going to increase and the pharmacology of HF will soon be tailored to genetic epidemiology. Despite the substantial research activity in the field of HF, relatively few coordinated studies have been conducted to assign a precise risk to specific gene polymorphisms. The translation of risk associated with genetic variations and translation of new knowledge into clinical practice will likely progress only when large well-designed studies will be conducted. With HF being one of the conditions of major impact now and destined to grow in the future, cardiologists must never forget to place their scientific and clinical initiatives with the vision of a prospective scenario in which the errors of today could carry serious consequences tomorrow, and investments for research could be negatively influenced by improper design, methodology, and plans for research.

Original languageEnglish
Pages (from-to)1173-1192
Number of pages20
JournalMedical Clinics of North America
Volume88
Issue number5
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Genetic Predisposition to Disease
Heart Failure
Research
Modifier Genes
Molecular Epidemiology
Protein Biosynthesis
Pharmacology
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic predisposition to heart failure. / Pasotti, Michele; Repetto, Alessandra; Tavazzi, Luigi; Arbustini, Eloisa.

In: Medical Clinics of North America, Vol. 88, No. 5, 09.2004, p. 1173-1192.

Research output: Contribution to journalArticle

Pasotti, Michele ; Repetto, Alessandra ; Tavazzi, Luigi ; Arbustini, Eloisa. / Genetic predisposition to heart failure. In: Medical Clinics of North America. 2004 ; Vol. 88, No. 5. pp. 1173-1192.
@article{00711bb38e9a44288097d83eb5b431d7,
title = "Genetic predisposition to heart failure",
abstract = "Because of its complexity, the list of susceptibility and modifier genes is going to increase and the pharmacology of HF will soon be tailored to genetic epidemiology. Despite the substantial research activity in the field of HF, relatively few coordinated studies have been conducted to assign a precise risk to specific gene polymorphisms. The translation of risk associated with genetic variations and translation of new knowledge into clinical practice will likely progress only when large well-designed studies will be conducted. With HF being one of the conditions of major impact now and destined to grow in the future, cardiologists must never forget to place their scientific and clinical initiatives with the vision of a prospective scenario in which the errors of today could carry serious consequences tomorrow, and investments for research could be negatively influenced by improper design, methodology, and plans for research.",
author = "Michele Pasotti and Alessandra Repetto and Luigi Tavazzi and Eloisa Arbustini",
year = "2004",
month = "9",
doi = "10.1016/j.mcna.2004.02.004",
language = "English",
volume = "88",
pages = "1173--1192",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Genetic predisposition to heart failure

AU - Pasotti, Michele

AU - Repetto, Alessandra

AU - Tavazzi, Luigi

AU - Arbustini, Eloisa

PY - 2004/9

Y1 - 2004/9

N2 - Because of its complexity, the list of susceptibility and modifier genes is going to increase and the pharmacology of HF will soon be tailored to genetic epidemiology. Despite the substantial research activity in the field of HF, relatively few coordinated studies have been conducted to assign a precise risk to specific gene polymorphisms. The translation of risk associated with genetic variations and translation of new knowledge into clinical practice will likely progress only when large well-designed studies will be conducted. With HF being one of the conditions of major impact now and destined to grow in the future, cardiologists must never forget to place their scientific and clinical initiatives with the vision of a prospective scenario in which the errors of today could carry serious consequences tomorrow, and investments for research could be negatively influenced by improper design, methodology, and plans for research.

AB - Because of its complexity, the list of susceptibility and modifier genes is going to increase and the pharmacology of HF will soon be tailored to genetic epidemiology. Despite the substantial research activity in the field of HF, relatively few coordinated studies have been conducted to assign a precise risk to specific gene polymorphisms. The translation of risk associated with genetic variations and translation of new knowledge into clinical practice will likely progress only when large well-designed studies will be conducted. With HF being one of the conditions of major impact now and destined to grow in the future, cardiologists must never forget to place their scientific and clinical initiatives with the vision of a prospective scenario in which the errors of today could carry serious consequences tomorrow, and investments for research could be negatively influenced by improper design, methodology, and plans for research.

UR - http://www.scopus.com/inward/record.url?scp=4444236082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444236082&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2004.02.004

DO - 10.1016/j.mcna.2004.02.004

M3 - Article

VL - 88

SP - 1173

EP - 1192

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 5

ER -